These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 33959579)

  • 1. Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D.
    Janse M; Brouwers T; Claassen E; Hermans P; van de Burgwal L
    Front Public Health; 2021; 9():612541. PubMed ID: 33959579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature.
    van de Burgwal LHM; Neevel AMG; Pittens CACM; Osterhaus ADME; Rupprecht CE; Claassen E
    Zoonoses Public Health; 2017 Dec; 64(8):599-611. PubMed ID: 28318148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model.
    Van de Burgwal LHM; Ribeiro CDS; Van der Waal MB; Claassen E
    Vaccine; 2018 Nov; 36(49):7496-7508. PubMed ID: 30420040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
    Beall RF; Kesselheim AS; Hollis A
    Clin Infect Dis; 2022 Jan; 74(2):347-351. PubMed ID: 33914860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct from the COVID-19 crisis: research and innovation sparks in Brazil.
    Rosa MFF; da Silva EN; Pacheco C; Diógenes MVP; Millett C; Gadelha CAG; Santos LMP
    Health Res Policy Syst; 2021 Jan; 19(1):10. PubMed ID: 33478499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming vaccine development.
    Black S; Bloom DE; Kaslow DC; Pecetta S; Rappuoli R
    Semin Immunol; 2020 Aug; 50():101413. PubMed ID: 33127296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COVID-19 Innovation System.
    Sampat BN; Shadlen KC
    Health Aff (Millwood); 2021 Mar; 40(3):400-409. PubMed ID: 33539184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
    Hanney SR; Wooding S; Sussex J; Grant J
    Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.
    Singh N; Rai SN; Singh V; Singh MP
    J Chem Neuroanat; 2020 Dec; 110():101874. PubMed ID: 33091590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient needs and research priorities in the enteral nutrition market - a quantitative prioritization analysis.
    Weenen TC; Jentink A; Pronker ES; Commandeur HR; Claassen E; Boirie Y; Singer P
    Clin Nutr; 2014 Oct; 33(5):793-801. PubMed ID: 24342258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics.
    Schwarzinger M; Watson V; Arwidson P; Alla F; Luchini S
    Lancet Public Health; 2021 Apr; 6(4):e210-e221. PubMed ID: 33556325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public Perspectives on COVID-19 Vaccine Prioritization.
    Persad G; Emanuel EJ; Sangenito S; Glickman A; Phillips S; Largent EA
    JAMA Netw Open; 2021 Apr; 4(4):e217943. PubMed ID: 33835172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine development and the way forward.
    Arora NK; Das MK
    Indian J Public Health; 2020 Jun; 64(Supplement):S108-S111. PubMed ID: 32496238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planning for COVID-19 vaccines safety surveillance.
    Kochhar S; Salmon DA
    Vaccine; 2020 Sep; 38(40):6194-6198. PubMed ID: 32684499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.